TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Generic drugmaker Mylan completes $1.75B acquisition in India

Email Newsletters

Click here to sign up for one of our email newsletters.

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

Thursday, Dec. 5, 2013, 12:01 a.m.
 

Generic drugmaker Mylan Inc. expanded its global manufacturing capability and portfolio of injectable medications with a $1.75 billion acquisition on Wednesday.

Cecil-based Mylan, one of the world's biggest generic pharmaceutical companies, said it completed the purchase of the Agila unit of Indian drugmaker Strides Arcolab Ltd.

The deal, first announced in February, gives Mylan 13 manufacturing plants in six countries and four research and development centers staffed by 400 scientists.

The addition of Agila's portfolio means Mylan offers more than 1,200 injectable drugs across the world, with another 900 products awaiting regulatory approvals, the company said.

Agila's foothold in several emerging markets, including Brazil, India and Southeast Asia, was attractive to Mylan.

“The acquisition of Agila will create a global injectables leader, expanding and strengthening Mylan's existing injectables platform and portfolio, and providing Mylan entry into exciting, new geographic markets,” CEO Heather Bresch said in a statement. “We believe we can generate significant growth from this business.”

Mylan will hold back $250 million in the deal on the condition that Agila satisfy U.S. regulators over problems of one of its Indian manufacturing plants.

In September, the Food and Drug Administration sent a so-called warning letter to Agila as a result of a June inspection at its Bangalore factory that turned up deficient procedures for preventing contamination of products.

Alex Nixon is a staff writer for Trib Total Media. He can be reached at 412-320-7928 or anixon@tribweb.com.

Add Alex Nixon to your Google+ circles.

Subscribe today! Click here for our subscription offers.

 

 

 


Show commenting policy

Most-Read Business Headlines

  1. U.S. Steel, Alcoa lead June decline
  2. United Airlines announces investment in biofuel supplier Fulcrum BioEnergy
  3. Obama overtime proposal slammed
  4. Stocks inch up but S&P ends quarter at loss
  5. Halliburton to close Indiana County office
  6. Consol again reworks offering for coal spinoff
  7. W.Pa. economy gains momentum as employers increase hiring
  8. Greek default drama plays out
  9. Data transfer in mergers tall task for chief information officer for Peoples Gas
  10. Supreme Court justices ream EPA for ignoring costs to meet air standards
  11. Pending home sales in U.S. climb to 9-year high